Genetic Counseling Services Market (2026-2036)

The growth of this market is mainly driven by the rapid expansion of genomic testing in oncology, reproductive health, and rare disease, each test requiring informed consent before testing and interpretation afterward; the increasing complexity of genomic results, including variants of uncertain significance and secondary findings that non-specialist clinicians are not equipped to interpret; the shortage of genetic counselors relative to testing volumes, which is driving investment in service models that extend their reach; and the growth of telehealth delivery, which removes the geographic constraint that previously limited access. In addition, progress toward direct reimbursement for genetic counselor services, the expansion of population and cascade testing programs, the growth of pharmacogenomic and cardiovascular genetic counseling, and the establishment of national genomic medicine programs in Europe, the Middle East, and Asia-Pacific are further supporting the growth of this market.

The Genetic Counseling Services Market, also referred to as the genetic counselling market, genomic counseling services market, or clinical genetics advisory services market, comprises the professional services through which trained counselors help patients and families understand genetic and genomic information, decide whether to undergo testing, interpret results, and act on them. The market includes pre-test counseling, covering indication assessment, family history, test selection, and informed consent; post-test counseling, covering result disclosure, interpretation of pathogenic variants, variants of uncertain significance, and secondary findings, risk communication, and management recommendations; cascade testing counseling for at-risk relatives; and variant reinterpretation and follow-up as classifications change. Services are delivered in person, by audiovisual telehealth, and by telephone, and are provided by hospital and health system genetics services, laboratory-employed counselors, independent telehealth providers, and physicians with genetics training. The market ecosystem extends from counselors and the organizations employing them to hospitals, cancer centres, reproductive and prenatal services, clinical laboratories, payers, employers, pharmaceutical companies, and patients and families.

Genetic counseling exists because a genomic result is not self-explanatory. A test may report a pathogenic variant that changes management for the patient and for relatives, a variant of uncertain significance that cannot yet be acted on, or a secondary finding unrelated to the reason for testing. Communicating what each means, what it does not mean, and what should follow requires training in both genetics and counseling, and doing it badly produces measurable harm, including unnecessary surgery, missed surveillance, and avoidable distress. As testing extends from specialist genetics clinics into oncology, cardiology, obstetrics, and primary care, the gap between the number of results generated and the number of clinicians able to interpret them has become the central constraint on genomic medicine.

Testing volumes set the scale of demand. In the second quarter of 2026, Natera, Inc. processed approximately 1,043,900 tests, up 22.4% year over year, including approximately 296,700 oncology tests, up 57.2%, illustrating the volume of genomic testing that generates demand for pre-test and post-test counseling. In the second quarter of 2026, Guardant Health, Inc. reported screening revenue of USD 52.9 million on approximately 66,000 Shield blood-based cancer screening tests, compared with approximately 16,000 a year earlier, and raised full-year guidance to 270,000-285,000 tests, indicating the scale at which population screening generates counseling requirements. Each test ordered creates a potential counseling requirement before and after, and population screening in particular generates counseling demand at a scale no specialist workforce can meet through traditional one-to-one appointments.

The workforce is growing quickly but from a small base. According to the National Society of Genetic Counselors, the American Board of Genetic Counseling had certified 5,629 genetic counselors as of 2021, up from 1,155 in 1999, representing growth of 100% since 2010, with approximately one certified genetic counselor per 75,000 people and approximately one clinical genetic counselor per 100,000 people. At roughly one clinical counselor per 100,000 people, the profession cannot absorb testing growth through headcount alone, and the arithmetic of the shortage is what drives most of the service innovation in this market, including group and digital pre-test education, counselor-extender models using genetic counseling assistants, risk-stratified triage so that specialist time is reserved for complex cases, and laboratory-employed counselors supporting ordering clinicians.

Telehealth has resolved the geographic component of access. The 2023 Professional Status Survey of the National Society of Genetic Counselors, which drew more than 3,000 respondents, projected that the workforce would grow 100% over the following ten years to more than 10,000 certified genetic counselors, reported that 82% of genetic counselors used audiovisual telehealth and that 90% of those providing direct patient care used more than one delivery model, up from 48% in 2019, and identified cancer genetics as the largest specialty at 34% of the profession. Audiovisual delivery allows a counselor in one state or country to serve patients anywhere licensure permits, which both improves access in areas with no local genetics service and allows employers and health plans to offer counseling as a covered benefit. In July 2026, Genome Medical, a telehealth genetic services company founded in 2016, marked its tenth anniversary, reporting more than 250,000 genetic counseling sessions delivered, more than 110,000 genetic tests facilitated, care delivered to patients in all 50 states, in-network relationships with health plans covering more than 148 million individuals, and a strategic shift announced in early 2025 toward rare disease, in which its share of patients grew threefold over two years. The strategic shift of that provider toward rare disease also illustrates where commercial value is concentrating, as genetically targeted therapies create a direct link between diagnosis and treatment.

Reimbursement has been the structural weakness of the market and is now changing. In January 2026, the Access to Genetic Counselor Services Act of 2026 was introduced in the U.S. Senate as S. 3607 and referred to the Committee on Finance, proposing to add covered genetic counseling services as a Medicare Part B benefit, to recognize state-licensed or board-certified genetic counselors as eligible providers, and to pay 80% of the lesser of the actual charge or 85% of the physician fee schedule amount, for services furnished on or after January 1, 2027. In the absence of Medicare recognition, counseling has frequently been delivered without direct payment, funded instead by hospital genetics departments, built into laboratory test pricing, or offered by laboratories as a service that supports test ordering. Direct billing would allow counseling to be sustained as a service in its own right, and would be expected to increase both the supply of counseling and the number of settings in which it is offered.

The market includes hospital and academic genetics services, which remain the largest providers overall, national reference and specialty laboratories that employ counselors to support testing, including Labcorp, Quest Diagnostics, Myriad Genetics, Natera, Invitae, GeneDx, and Exact Sciences, and independent telehealth providers such as Genome Medical, InformedDNA, and Genetic Support Foundation. Participants compete and differentiate on counselor availability and turnaround, specialty depth, licensure coverage across jurisdictions, integration with ordering workflows and electronic health records, payer contracting, and patient experience.

At the same time, the market faces challenges, including the workforce shortage itself, which limits how quickly services can scale, the absence in most jurisdictions of a billing mechanism that recognizes counselors as providers, variation in state and national licensure that constrains cross-border telehealth, difficulty demonstrating the economic value of counseling to payers, uneven integration with ordering clinicians, and the risk that testing proceeds without counseling where no counselor is available. As a result, providers that combine scalable service models, broad licensure coverage, secured reimbursement, specialty depth in oncology and rare disease, and demonstrable integration with testing workflows are expected to capture the largest share of growth over the forecast period.